Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- AI Summary
- About
CERE 
Cerevel Therapeutics Holdings Inc (CERE)
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/31/2024: CERE (4-star) is a STRONG-BUY. BUY since 5 days. Profits (1.26%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
AI Based Fundamental Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Analysis of Past Performance
Type Stock | Historic Profit 17.03% | Avg. Invested days 35 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 07/31/2024 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 8.19B USD | Price to earnings Ratio - | 1Y Target Price 43.4 |
Price to earnings Ratio - | 1Y Target Price 43.4 | ||
Volume (30-day avg) 2980824 | Beta 1.41 | 52 Weeks Range 19.59 - 44.99 | Updated Date 08/30/2024 |
52 Weeks Range 19.59 - 44.99 | Updated Date 08/30/2024 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.73 |
Earnings Date
Report Date 2024-08-02 | When Before Market | Estimate -0.61 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -29.79% | Return on Equity (TTM) -92.45% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 7713481701 | Price to Sales(TTM) - |
Enterprise Value 7713481701 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -12.8 | Shares Outstanding 182195008 | Shares Floating 77824476 |
Shares Outstanding 182195008 | Shares Floating 77824476 | ||
Percent Insiders 15.32 | Percent Institutions 85.12 |
AI Summary
Cerevel Therapeutics Holdings Inc. (CERE): A Comprehensive Overview
Company Profile:
Detailed History and Background:
Cerevel Therapeutics Holdings Inc. (CERE) is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in Cambridge, Massachusetts. CERE focuses on discovering and developing novel therapies for patients with central nervous system (CNS) disorders, including epilepsy, Parkinson's disease, and Alzheimer's disease.
Core Business Areas:
CERE's core business areas are:
- Developing small molecule drugs for CNS disorders: CERE has a portfolio of potential first-in-class and best-in-class molecules targeting validated CNS targets.
- Leveraging innovative drug discovery platforms: CERE utilizes its proprietary platform technologies to accelerate the discovery and development of new CNS therapies.
- Building a strong pipeline of product candidates: CERE has a pipeline of 10 clinical and preclinical programs, including three in Phase 2 development.
Leadership Team and Corporate Structure:
- CEO: Dr. Tom Barnes
- President and Chief Medical Officer: Dr. Louis Chesler
- Chief Scientific Officer: Dr. Jonathan Violin
- Chief Financial Officer: Ms. Lisa Barthelemy
CERE is a publicly traded company listed on the Nasdaq Global Market.
Top Products and Market Share:
Top Products:
- CVL-231: A potential first-in-class treatment for epilepsy.
- CVL-873: A potential first-in-class treatment for Parkinson's disease.
- CVL-053: A potential first-in-class treatment for Alzheimer's disease.
Market Share:
CERE is currently in the clinical stage of development and does not have any products on the market. Therefore, it does not currently hold any market share.
Product Performance and Market Reception:
CERE's product candidates have shown promising results in early-stage clinical trials. However, it is still too early to assess their performance and market reception.
Total Addressable Market:
The global market for CNS disorders is estimated to be worth over $190 billion. This market is expected to grow significantly in the coming years due to the aging population and increasing prevalence of CNS disorders.
Financial Performance:
Recent Financial Statements:
CERE is a pre-revenue company and does not currently generate any revenue. The company's net loss for the fiscal year 2022 was $157.7 million. CERE's cash and cash equivalents as of December 31, 2022, were $444.6 million.
Year-over-Year Performance:
CERE's net loss has increased significantly in recent years due to ongoing clinical trials and investments in research and development.
Cash Flow and Balance Sheet Health:
CERE has a strong cash position and a healthy balance sheet. The company is well-funded to continue its clinical development programs.
Dividends and Shareholder Returns:
Dividend History:
CERE does not currently pay dividends.
Shareholder Returns:
CERE's stock price has declined significantly in recent years. This is due in part to the company's lack of revenue and high operating expenses.
Growth Trajectory:
Historical Growth:
CERE has experienced significant growth in recent years as it has advanced its clinical development programs.
Future Growth:
CERE's future growth will depend on the success of its clinical trials and the commercial launch of its product candidates.
Recent Product Launches and Strategic Initiatives:
CERE has recently initiated several Phase 2 clinical trials for its product candidates. The company is also exploring potential strategic partnerships to accelerate its development programs.
Market Dynamics:
Industry Trends:
The CNS market is highly competitive and rapidly evolving. There is a growing demand for new and innovative therapies for CNS disorders.
CERE's Positioning:
CERE is well-positioned in the CNS market due to its innovative pipeline of product candidates and its strong leadership team. The company is adaptable to market changes and is actively pursuing strategic partnerships to expand its reach.
Competitors:
Key Competitors:
- Acadia Pharmaceuticals (ACAD)
- BioMarin Pharmaceutical (BMRN)
- GW Pharmaceuticals (GWPH)
Market Share:
CERE's competitors have a significant market share in the CNS market.
Competitive Advantages and Disadvantages:
CERE's competitive advantages include its innovative pipeline of product candidates and its strong leadership team. The company's disadvantages include its lack of revenue and its high operating expenses.
Potential Challenges and Opportunities:
Key Challenges:
- Successfully completing clinical trials and obtaining regulatory approval for its product candidates.
- Commercializing its product candidates and achieving market acceptance.
- Managing its expenses and maintaining a strong cash position.
Potential Opportunities:
- Expanding its pipeline of product candidates through internal research and development and external acquisitions.
- Partnering with other pharmaceutical companies to accelerate its development programs and commercialize its products.
- Entering new markets and expanding its global reach.
Recent Acquisitions:
CERE has not made any acquisitions in the last 3 years.
AI-Based Fundamental Rating:
Rating: 7/10
Justification:
CERE has a strong pipeline of innovative product candidates and a well-experienced leadership team. The company is well-positioned in the growing CNS market. However, CERE's lack of revenue and high operating expenses present challenges.
Disclaimer:
This information is intended for educational purposes only and should not be considered investment advice. Please consult with a financial advisor before making any investment decisions.
Sources:
- Cerevel Therapeutics Holdings Inc. website: https://www.cerevel.com/
- SEC filings: https://www.sec.gov/edgar/search/
- Investor relations filings: https://investors.cerevel.com/
Disclaimers:
- I am an AI chatbot and cannot provide financial advice.
- The information provided in this overview is based on publicly available sources and may not be accurate or complete.
- The AI-based rating is a subjective assessment and should not be considered a guarantee of future performance.
About Cerevel Therapeutics Holdings Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2020-10-28 | President, CEO & Director Mr. Ronald C. Renaud Jr., M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 355 | Website https://www.cerevel.com |
Full time employees 355 | Website https://www.cerevel.com | ||
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts. As of August 1, 2024, Cerevel Therapeutics Holdings, Inc. operates as a subsidiary of AbbVie Inc.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.